(Q34294938)

1 August 2017

1 reference

title

Effects of immunosuppression and organ transplantation on the natural history and immunopathogenesis of hepatitis C virus infection (English)

1 reference

1 August 2017

organ transplantation

1 reference

1 reference

1 reference

1 reference

McCaughan GW

1

1 reference

PubMed ID

11429029

1 August 2017

Zekry A

series ordinal

2

1 reference

1 August 2017

1 December 2000

1 reference

Transplant Infectious Disease

1 August 2017

1 reference

1 August 2017

2

1 reference

1 August 2017

4

1 reference

1 August 2017

166-185

1 reference

The scientific challenge of hepatitis C.

1 August 2017

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

High Rate of Infectivity and Liver Disease in Blood Donors with Antibodies to Hepatitis C Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

The Declining Risk of Post-Transfusion Hepatitis C Virus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Anti-hepatitis C virus screening will reduce the incidence of post-transfusion hepatitis C also in low-risk areas

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Hepatitis C virus: the major causative agent of viral non-A, non-B hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Genetic organization and diversity of the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Detection of hepatitis C viral sequences in non-A, non-B hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Characterization of aggregates of hepatitis C virus glycoproteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Binding of hepatitis C virus to CD81

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Is CD81 the key to hepatitis C virus entry?

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

A second hepatitis C virus-encoded proteinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

C-terminal domain of the hepatitis C virus NS3 protein contains an RNA helicase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Characterization of RNA binding activity and RNA helicase activity of the hepatitis C virus NS3 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Mutations in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Mutations in NS5A region of hepatitis C virus genome correlate with presence of NS5A antibodies and response to interferon therapy for most common European hepatitis C virus genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Genetic Heterogeneity of Hepatitis C Virus: Quasispecies and Genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Review: molecular epidemiology of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Genetic heterogeneity of hepatitis C virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Hepatitis C virus quasispecies populations during chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

The quasispecies of hepatitis C virus and the host immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Relation of disease activity during chronic hepatitis C infection to complexity of hypervariable region 1 quasispecies

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Clinical relevance of hepatitis C virus quasispecies

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Assessment of long-term outcomes of hepatitis C virus infection in a cohort of patients with acute hepatitis in 1971-1975: results of a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Clinical outcomes after transfusion-associated hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Prognosis of chronic hepatitis C: results of a large, prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Hepatitis C virus infection is an additive risk factor for development of hepatocellular carcinoma in patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

A role for hepatitis C virus infection in type II cryoglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Hepatitis C virus and essential mixed cryoglobulinaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Antibodies to hepatitis C virus in essential mixed cryoglobulinaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

IgM and IgG antibodies to hepatitis C virus in patients with mixed cryoglobulinaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Cryoglobulinemia with vasculitis associated with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Extrahepatic manifestations of HCV infection: facts and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Membranoproliferative glomerulonephritis associated with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Hepatitis C virus infection, mixed cryoglobulinemia, and non-Hodgkin's lymphoma: an emerging picture

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Hepatitis C virus infection in patients with non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Hepatitis C virus infection and B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Lymphotropic virus infection of peripheral blood mononuclear cells in B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Hepatitis C virus and non-Hodgkin's lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Hepatitis C virus infection in mixed cryoglobulinemia and B-cell non-Hodgkin's lymphoma: evidence for a pathogenetic role

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Renal manifestations of hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Cryoglobulinemic membranoproliferative glomerulonephritis associated with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Treatment strategies for chronic hepatitis C: update since the 1997 National Institutes of Health Consensus Development Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Long-term follow-up of patients with chronic hepatitis C treated with α-interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Antiviral therapy of hepatitis C--present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Risk factors for cirrhosis in patients with chronic hepatitis C virus infection: results of a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Regression of hepatic fibrosis in hepatitis C with long-term interferon treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

The changes in quantitative HCV RNA titers during interferon alpha 2B therapy in patients with chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Relationship between biochemical and virological responses to interferon therapy in chronic hepatitis C infection. Consensus Interferon Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Review article: interferon and hepatitis C--factors predicting therapeutic outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. The Consensus Interferon Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Therapy of hepatitis C: alpha interferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Factors predictive of a beneficial response to therapy of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, Franc

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Interferon-alpha plus ribavirin in chronic hepatitis C resistant to previous interferon-alpha course: results of a randomized multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Prevalence of cryoglobulinemia in chronic hepatitis C virus infection and response to treatment with interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Successful treatment of HCV-associated cryoglobulinaemic glomerulonephritis with a combination of interferon-alpha and ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Intrahepatic hepatitis C RNA levels do not correlate with degree of liver injury in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Hepatitis C virus-associated fulminant hepatic failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Reactivation of chronic hepatitis C after withdrawal of immunosuppressive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Inhibition of tumor necrosis factor (TNF-alpha)-mediated apoptosis by hepatitis C virus core protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Lack of Protective Immunity Against Reinfection with Hepatitis C Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Limited humoral immunity in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

The role of CD4 and CD8 T cells in viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

A helper T-cell antigen enhances generation of hepatitis C virus-specific cytotoxic T lymphocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Conserved hepatitis C virus sequences are highly immunogenic for CD4(+) T cells: implications for vaccine development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Immunobiology of hepatitis C virus (HCV) infection: the role of CD4 T cells in HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Immunopathology of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

The role of immune responses in the pathogenesis of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Cytotoxic T cells and viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Analysis of a successful immune response against hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

How viruses escape from cytotoxic T lymphocytes: molecular parameters and players

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Cytotoxic T lymphocyte response and viral load in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Viral mutations, TCR antagonism and escape from the immune response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Hepatitis C virus (HCV) genotype, tissue HCV antigens, hepatocellular expression of HLA-A,B,C, and intercellular adhesion-1 molecules. Clues to pathogenesis of hepatocellular damage and response to interferon treatment in patients with chronic hepat

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Chemokine receptors and T cell chemotaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Serum interleukin 4 and interleukin 10 levels in patients with chronic hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Reinfection of liver graft by hepatitis C virus after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Long-term outcome of hepatitis C infection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Recurrent and new hepatitis C virus infection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Long-term outcome of hepatitis C virus infection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Predictors of patient and graft survival following liver transplantation for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

A prospective study of hepatitis C virus infection in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Impact of hepatitis B and C virus on kidney transplantation outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Outcomes of hepatitis C positive (HCV+) heart transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Outcome of de novo hepatitis C virus infection in heart transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

A longitudinal analysis of hepatitis C virus replication following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Cholestatic hepatitis after liver transplantation is associated with persistently high serum hepatitis C virus RNA levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Cholestatic hepatitis C in liver allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Post-transplant quasispecies pattern remains stable over time in patients with recurrent cholestatic hepatitis due to hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Antibodies to hepatitis C virus envelope proteins correlate with hepatitis C viraemia after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Role of hepatitis C virus in lymphoproliferative disorders after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Outcome of hepatitis C virus-associated membranoproliferative glomerulonephritis after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Hepatitis C in HIV-infected patients with and without AIDS: prevalence and relationship to patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Ribavirin therapy for hepatitis C infection following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

A pilot study of ribavirin therapy for recurrent hepatitis C virus infection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Ribavirin and interferon for recurrent posttransplantation HCV infection: to treat or not to treat?

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Prophylaxis against HCV recurrence after liver transplantation: effect of interferon and ribavirin combination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Screening and confirmatory testing of cadaver organ donors for hepatitis C virus infection: a U.S. National Collaborative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Prevalence of hepatitis C virus RNA in organ donors positive for hepatitis C antibody and in the recipients of their organs

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Hepatitis C infection and post-transplantation liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Dynamic behavior of hepatitis C virus in chronically infected patients receiving liver graft from infected donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

The importance of preventing hepatitis C virus infection among injection drug users in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Identification of a highly conserved sequence element at the 3' terminus of hepatitis C virus genome RNA

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Hepatitis C virus NS3 serine proteinase: trans-cleavage requirements and processing kinetics

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Hepatitis C virus-encoded nonstructural protein NS4A has versatile functions in viral protein processing

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Immunity in chimpanzees chronically infected with hepatitis C virus: role of minor quasispecies in reinfection

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

The natural history of hepatitis C

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Clinical outcome of hepatitis C as a function of mode of transmission

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Extrahepatic manifestations of hepatitis C

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Detection of occult low-grade B-cell non-hodgkin's lymphoma in patients with chronic hepatitis C infection and mixed cryoglobulinemia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Hepatitis C associated glomerulonephritis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Treatment of chronic hepatitis C by interferon for longer duration than six months

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Persistent hepatitis C viraemia without liver disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Hepatitis C virus core protein interacts with the cytoplasmic tail of lymphotoxin-beta receptor

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Immunopathogenesis of viral hepatitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Expression of cytokine-dependent immune adhesion molecules by hepatocytes and bile duct cells in chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Chronic liver dysfunction in heart transplant recipients, with special reference to viral B, C, and non-A, non-B, non-C hepatitis. A retrospective study in 80 patients with follow-up of 60 months

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Donor-recipient sharing of HLA class II alleles predicts earlier recurrence and accelerated progression of hepatitis C following liver transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Immunohistochemical evidence of immunopathogenetic mechanisms in chronic hepatitis C recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Combined liver and kidney transplantation in patients with chronic nephritis associated with end-stage liver disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Long-term results of combined kidney and liver transplantation at one center

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Interferon-alpha therapy for hepatitis C virus infection after liver transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Retransplantation for recurrent hepatitis C

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Clinical characteristics affecting the outcome of liver retransplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Treatment of chronic hepatitis B and C with alpha interferon in a renal transplant patient

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

Transmission of hepatitis C by kidney transplantation--the risks

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020403.X

7 January 2021

10.1034/J.1399-3062.2000.020403.X

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

11429029